Analyst firms · BofA Securities · LLY

BofA Securities LLY price target and rating history

Eli Lilly and Company (LLY) · Health Care

BofA Securities rates Eli Lilly and Company (LLY) Buy with a $1,268 price target, as of its latest action on Dec 15, 2025. It has published 4 rating actions on LLY since December 2021, including 0 upgrades and 0 downgrades. Across 9 firms with a LLY price target in the last 12 months, the median target is $1,250. BofA Securities's $1,268 is 1% above that.

Current rating
Buy
Price target
$1,268
Median target, all firms
$1,250
Actions on LLY
4

BofA Securities price target on LLY

$1,268$784$30020222023202420252026
BofA Securities price target on LLY, each point a stated target, December 2021 to December 2025.

Every BofA Securities rating on LLY

How other firms rate LLY

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BerenbergBuy$1,400Sep 15, 2026
HSBCReduce$850Mar 17, 2026
RBC Capital MarketsOutperform$1,250Feb 25, 2026
BarclaysOverweight$1,350Feb 20, 2026
UBSBuy$1,250Jan 7, 2026
DaiwaBuy$1,230Dec 16, 2025
Goldman SachsBuy$1,145Dec 15, 2025
BofA SecuritiesBuy$1,268Dec 15, 2025
ScotiabankSector Outperform$1,165Nov 13, 2025

Questions about BofA Securities and LLY

What is BofA Securities's price target for LLY?
BofA Securities's latest stated price target for Eli Lilly and Company (LLY) is $1,268, from its action on Dec 15, 2025.
What is BofA Securities's rating on LLY?
BofA Securities rates LLY Buy, a bullish rating, as of Dec 15, 2025.
When did BofA Securities last change its view on LLY?
On Dec 15, 2025, BofA Securities cuts its price target to $1,268 from $1,286, keeps Buy.
How does BofA Securities's LLY target compare with other analysts?
Across 9 firms with a LLY price target in the last 12 months, the median target is $1,250. BofA Securities's $1,268 is 1% above that.

More LLY rating histories

All BofA Securities ratingsLLY news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.